Published: Dec. 8, 2025 at 9:12 a.m. ET Structure Therapeutics’ stock soared toward an 18-month high in…
development
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
Published: Dec. 3, 2025 at 2:05 p.m. ET Bristol Myers Squibb needs more time to run a…
Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles
Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a…
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.
Arm steps up its AI investments as it cashes in on another billion-dollar quarter
Arm says its rising revenue allows it to spend up on research and development that helps…
There’s still hope GLP-1 drugs could slow the second-biggest type of dementia
Published: Nov. 24, 2025 at 4:57 p.m. ET There’s rarely good news about Alzheimer’s disease, but a…